Lynne Sullivan - Jun 24, 2021 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Role: CFO & Head of Corp. Dev.
Signature: /s/ Alexander Nguyen, Attorney-in-Fact for Lynne Marie Sullivan
Stock symbol: UBX
Transactions as of: Jun 24, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/28/2021, 05:17 PM
Previous filing: Jun 24, 2021
Next filing: Jul 30, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	UBX	Common Stock, $0.0001 par value	Award	$0	+30.8K	+12.85%	$0.00	271K	Jun 24, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	UBX	Stock Option (Right to Buy)	Award	$0	+123K		$0.00	123K	Jun 24, 2021	Common Stock	123K	$4.18	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from June 24, 2021. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2	Includes RSUs which vest over time measured from the grant date.
F3	Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.